- Active not recruitingPHASE3
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
This study looks at a new drug combination, pozelimab and cemdisiran, for adults with a rare blood condition called PNH. We want to see how safe and effective it is compared to existing treatments, ravulizumab and eculizumab. It's for people who haven't recently had certain PNH treatments.
For: Paroxysmal Nocturnal HemoglobinuriaUnited States · Brazil · Canada - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
For: Immunoglobulin A Nephropathy · IgANUnited States · Argentina · Australia - RecruitingPHASE3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
This study looks at a new medicine called ravulizumab for adults receiving a kidney transplant from a deceased donor. It aims to see if this medicine can help their new kidney start working well faster, reducing the need for dialysis after the operation.
For: Delayed Graft Function · DGF · Kidney TransplantUnited States · Argentina · Australia - Not yet recruitingPHASE4
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
This study compares five medicines for Neuromyelitis Optica Spectrum Disorder (NMOSD) affecting the eyes and spinal cord. It aims to find which treatment best prevents relapses and has the fewest side effects for adults with NMOSD.
For: NMOSDUnited States · Germany - Active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
For: Chronic Kidney Disease · CKD · Cardiac DiseaseUnited States · Argentina · Australia